Salvage radiotherapy for recurrence of localized prostate cancer after high-intensity focused ultrasound (HIFU)  by Wu, Yen-Ting et al.
Abstracts / Urological Science 27 (2016) S36eS52 S49signiﬁcant improvement of PPBC at 1st and 3rd month compared with
baseline in younger group (P<0.05). In older group, the score of QoL and
OABSS were signiﬁcantly decreased at 1st and 3rd month compared with
baseline. (P<0.05).The mean changes of most measurements after 3
months of treatment were no signiﬁcant difference between younger and
older patients, except Qmax and voided volume. Younger patients expe-
rience more AEs than the elders (26.79% vs 12.5%) during treatment. The
common AEs included dry mouth (n¼5), abdominal distension (n¼3) and
dizziness (n¼3). Nevertheless, the incidence of AEs when using mirabe-
gron were acceptable low in two groups.
Conclusion: Mirabegron 25 mg once daily is a safe and effective drug to
improve OAB symptoms and QoL in old patients with multiple comor-
bidities. The treatment efﬁcacy were no much difference between younger
and older patients.
MP5-8.
SUBJECTIVE SYMPTOM IMPROVEMENT OF SILODOSIN TREATMENT FOR
BPH PATIENTS WITH UNSATISFACTORY RESPONSE TO INITIAL ɑ1
BLOCKER
Han-Yu Weng, Chien-Hui Ou. Department of Urology, Medical College and
Hospital, National Cheng-Kung University, Tainan, Taiwan
Purpose: To evaluate subjective symptoms improvement of Silodosin
treatment for BPH patients with unsatisfactory response to initial ɑ1
blocker.
Materials and Methods: 50 patients diagnosed with BPH and reported
with unsatisfactory response to initial ɑ1 blocker were included in this
study. IPSS were recorded before and after administration of 4 weeks of
Silodosin. No drug withdrawal period was provided when switching the
drug. We evaluate subjective improvement of Silodosin treatment ac-
cording to the International Prostate Symptom Score.
Results: 28 patients (56 %) had subjective improvement according to the
International Prostate Symptom Score total score but 22 patients failed to
have symptoms improvement. Comparison of symptoms revealed that
Silodosin showed signiﬁcant effect on nocturia. The most frequent adverse
drug reaction was ejaculatory disorder with Silodosin.
Conclusion: Silodosin exhibits some efﬁcacy in improving subjective
symptoms especially in nocturia for BPH patients with unsatisfactory
response to initial ɑ1 blocker
MP5-9.
WHETHER A GOOD UROFLOW RATE COULD GUARANTEE A LOW POST-
VOID RESIDUAL URINE VOLUME IN MEN WITH OVERACTIVE BLADDER?
Kuan-Jung Lin 1, Chih-Chieh Lin 1,2,3, Alex Tong-Long Lin 1,2,3, Kuang-Kuo
Chen 1,2,3. 1Department of Urology, Taipei Veterans General Hospital, Taipei,
Taiwan; 2Department of Urology, School of Medicine, National Yang-Ming
University, Taipei, Taiwan; 3 Shu-Tien Urological Science Research Center,
Taipei, Taiwan
Purpose: When considering antimuscarinics for patients with overactive
bladder (OAB), post-void residual urine volume (PVR) is an important
factor for decision-making. Using antimuscarinics in patients with a large
amount PVR is not desirable. It is a reasonable inference that patients with
good ﬂow rates should be able to empty their bladders to achieve a low
PVR. If this hypothesis is correct, then antimuscarinics can be used safely in
OAB patients with good ﬂow rate without the need to check PVR. This
study tested this hypothesis by evaluating the correlation between uroﬂow
rate and PVR in men with OAB symptom.
Materials and Methods: We retrospectively recruited male OAB patients,
who had urgency with or without urge incontinence, between Aug 2008
and July 2015. Exclusion criteria included urinary tract infection, prostate
and bladder cancer. Patients with abdominal strain pattern or inadequate
voided volume (less than 150ml) on uroﬂowmetry (UFR) were excluded.
Patients were categorized into good Qmax and low Qmax groups by the
cut-off value of 15ml/sec maximal ﬂow rate (Qmax) in free uroﬂowmetry.
All patients received pressure ﬂow studies for evaluating bladder outlet
obstruction (BOO) and transabdominal ultrasonography for evaluating the
prostatic size, intra-vesical prostatic protrusion (IPP) and detrusor wall
thickness (DWT). BOO was deﬁned by BOOI>40. Amounts of residual urinewere determined by post-void catheterization. International Prostate
Symptom Score (IPSS) and Overactive Bladder Symptom Score (OABSS)
were collected for symptom evaluation.
Results: A total of 136 male patients with OAB symptoms were enrolled.
The patients’ demographic was showed in table 1. Patients with good
Qmax group were signiﬁcantly younger. Patients with good Qmax had
lower scores in the total score of IPSS and voiding subscore. Nocturia as
evaluated by IPSS and OABSS was more severe in patients with low Qmax
group. PVR in good Qmax group was signiﬁcantly less than that in low
Qmax group (49.3±39.0 vs 82.7±79.6, p¼0.04). However, in good Qmax
group, 15.7% patients had PVR more than 100ml and 7.1% had PVR more
than 200ml. More patients in low Qmax group had BOO than those in good
Qmax group (48.6% vs 24.2%, p¼0.03)
Conclusion: Male OAB patients with maximal uroﬂow rate higher than
15ml/sec have lower PVR. Nevertheless, clinical signiﬁcant high PVRmight
still present in patients with good ﬂow rate. It is still necessary to measure
PVR even in patients with a satisfactory uroﬂow rate.
MP5-10.
THE EFFECT OF LOW-INTENSITY EXTRACORPOREAL SHOCK WAVE
THERAPY FOR CHRONIC PELVIC PAIN SYNDROME
Chia-Chun Tsai 1,2, Chia-Chu Liu 1,2,3, Hsiang-Ying Lee 1,2, Jiun-Hung
Geng 1,4, Ching-Chia Li 1,2, Wen-Jeng Wu1,2, Chii-Jye Wang 1. 1Department
of Urology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan;
2Department of Urology, Kaohsiung Municipal Ta-Tung Hospital,
Kaohsiung, Taiwan; 3Department of Urology, Ministry of Health and
Welfare Ping-Tung Hospital, Pingtung, Taiwan; 4Department of Urology,
Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung, Taiwan
Purpose: To assess the safety and efﬁcacy of the treatments performed
with low-intensity extracorporeal shockwave therapy (LI-ESWT) on
symptomatic chronic pelvic pain syndrome (CPPS) patients.
Materials and Methods: We design a prospective, blind and randomized
controlled trial for patients with CPPS. All patients have once LI-ESWT per
week for 4 weeks. Use questionnaire of pre-treatment and post-treatment
to assess the safety and efﬁcacy.
Results: The National Institutes of Health Chronic Prostatitis Symptom
Index (NIH-CPSI) scores, especially CPSI pain domain, of enrolled patient
were improved after 4 times LI-ESWT. More than half patients who got LI-
ESWT had symptomatic improvement after ﬁst treatment. There is a ten-
dency to improve sexual quality after full therapeutic regimen. No patients
have ecchymosis, intolerable pain or other complication during LI-ESWT.
Conclusion: We describe our experience of LI-ESWT for CPPS patients. In
this pilot study, LI-ESWT can improve quality of life for CPPS patients
without complications.
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MP6-1.
SALVAGE RADIOTHERAPY FOR RECURRENCE OF LOCALIZED PROSTATE
CANCER AFTER HIGH-INTENSITY FOCUSED ULTRASOUND (HIFU)
Yen-Ting Wu 1,2, Guan-Lin Huang 1,2, Fu-Min Fang 1,2, You-Ming Wang 1,2,
Chun-Chien Hsu 1,2, Yao-Chi Chuang 1,2, Po-Hui Chiang 1,2. 1Department of
Urology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan;
2Department of Radiation Oncology, Kaohsiung Chang Gung Memorial
Hospital, Kaohsiung, Taiwan
Purpose: Despite increasing application of high-intensity focused ultra-
sound (HIFU), there was few published experience regarding to salvage
management for recurrent localized prostate cancer. We aim to evaluate
tolerance and oncologic control with salvage radiotherapy (SRT) after HIFU
failure and to identify predictive factors of success.
Materials and Methods: In this single-centre retrospective study, retro-
spective analysis on 121 localized prostate cancer patients status post the
HIFU therapy from December 2009 to July 2015 were performed with
perioperative data. Total 11 patients underwent salvage radiotherapy with
dose ranging from 2400-7200 cGy. The median dose of conformal treat-
ment was 7000 cGy. The primary outcome measure was progression-free
Abstracts / Urological Science 27 (2016) S36eS52S50survival (PFS) deﬁned as no biochemical relapse (two consecutive rises in
prostate-speciﬁc antigen [PSA] with a velocity>0.4 ng/ml per year or PSA
>1.5 ng/ml) and no additional treatment. Adverse events in terms of
genitourinary and gastrointestinal toxicity were reported.
Results: Themean follow-up of the 121 patients was 32.7months and total
11 patients underwent salvage radiotherapy. Six patients received SRT and
hormone therapy. Five patients received SRT alone. 6-month progression-
free survival was observed in total 6 patients receiving SRT and hormone
therapy achieved. However, biochemical relapse was documented in two
patients, 9.47 and 12.20 months after salvage treatment completed,
respectively. Among 5 patients receiving SRT alone, two patients
encountered treatment failure. There is 1 patient who had histologically
proven local relapse. 6-month progression-free survival was observed in
the other 2 patients. Salvage radiotherapy was discontinued on 1 patient,
who developed grade 4 ileus after 2400 cGy of radiation. There was also 2
patients getting grade 3 gastrointestinal toxicity, bloody stool and anal
ulcer with bleeding, respectively. Otherwise, gastrointestinal toxicity was
low. All genitourinary toxicity are grade 1e2. Three patients had no
genitourinary symptom.
Conclusion: In this preliminary study, combined radiotherapy and hor-
mone therapy seemed provided satisfactory oncologic control after for
salvage treatment after primary HIFU failure. Though genitourinary and
gastrointestinal toxicity were usually low, Grade 3e4 toxicity was still
noted. These results warrant further and longer investigation.
MP6-2.
PSA FLARE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
PATIENTS TREATED WITH ABIRATERONE OR DOCETAXEL
Hui-Ying Liu, Yuan-Chi Shen, Cheng-Jen Yu, Po-Hui Chiang. Division of
Urology, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University
College of Medicine, Taiwan
Purpose: The aim of this study was to assess PSA ﬂare up phenomenon in
the treatment of metastatic castration-resistant prostate cancer (mCRPC)
patients with abiraterone or docetaxel and to correlate with clinical
outcome.
Materials and Methods: We retrospectively evaluated 92 patients with
metastatic castrate-resistant prostate cancer (CRPC) either treated with
abiraterone or docetaxel at our institution. Baseline serum PSA levels were
checked before treatment and followed bymonitoring every 4weeks in the
group of abiraterone and every cycle in the groupof docetaxel. The PSAﬂare
phenomenonwas evaluated. Clinical outcomes were evaluated to compare
survival between groups of patients according to variations of PSA level.
Results: Of 92 patients, 73 patients received docetaxel therapy and 19
patients treated with abiraterone. They were classiﬁed into four groups:
stabilization (PSA decline <50%), PSA progression, primary responder (PSA
decline S 50%), and ﬂare-up phenomenon. Six patients (8.2%) got doce-
taxel therapy and two patients (10.5%) got abiraterone therapy were
identiﬁed with PSA ﬂare phenomenon. We compared the overall survival
between group of PSA decline> 50% with the ﬂare-up group. There was no
statistical difference in survival between two groups.
Conclusion: There is a considerable portion of mCRPC patients experience
PSA ﬂare under either abiraterone or docetaxel therapy. There was no
statistical difference in survival between PSA responder and PSA ﬂare-up
phenomenon group. Patients should be informed of this effect to avoid
early, and thereby inadequate, discontinuation of treatment.
MP6-3.
SYSTEMIC REVIEW OF MALIGNANCY AFTER ILEOCYSTOPLASTY
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The incidence of post-ileocystoplasty malignancy is low and
most published reports were case reports and only few single-cancer
retrospective cohort study presented. Therefore, we systemically reviewed
the published reports to pool the results for analysis to more clearly
illustrate the characteristics and prognosis of malignancy associated with
ileocystoplasty.Materials and Methods: We did a systemic search of the PubMED® and
CiNii for all cases with the following keywords: cystoplasty, enter-
ocystoplasy, ileocystoplasty, ileum, urinary diversion, and malignancy or
bladder cancer. The additional records on this topic were identiﬁed from
references cited in the selected articles and previous review articles on this
topic. Two of the authors (CWL and SJC) independently did the literature
search and data extraction. The parameters retrieved from the reports
included baseline patient characteristics, latency period, indications for
surgery, presenting symptoms and signs, histological type, locus of tumor,
follow-up period and survival which were analyzed with commercial
software (Medcalc®, version 9.3, USA).
Results: There were 41 articles selected and analyzed prudently with 56
cases included in the review. The reported incidence ranged from 0.9% to
5.5% in patients underwent ileocystoplasty. The average age was
53.0 ± 11.8 years old. Most malignancy occurred 15 years after ileocysto-
plasty (47/56, 83.9%) and the most commonly presenting symptoms were
gross hematuria (60.0%). The locations of malignancy were mainly located
at the ileobladder junction. Adenocarcinoma is most commonly observed
histology among all cases (39/56) while urothelial carcinoma predomi-
nated in cases with neurogenic bladder (5/10). 17 of 45 patients (37.8%)
presented with advanced disease and poor prognosis (median survival
time was 6.0 months).
Conclusion: The systemic review revealed low incidence of post-ileocys-
toplasty malignancy with majorly poor prognosis. Yearly cystoscopy sur-
veillance may not be indicated in case within 15 years post-operatively
except symptomatic patients.
MP6-4.
A PRELIMINARY REPORT: THE APPLICATION OF HO-YAG LASER IN
TURBT WITH ENBLOC METHOD
Chi-Wen Lo, Shang Jen Chang, Chang-Hsin Hsieh, Shei-Dei Yang. Divisions
of Urology, Department of Surgery, Taipei Tzu Chi Hospital, New Taipei,
Taiwan
Purpose: The traditional TURBT surgery still have several drawbacks
include fragmentation, cauterization effect and easily disorientation. In
here, we reviewed our patients receiving laser en bloc TURBT to compared
the traditional TURBT with the feasibility, oncology outcome and
complication rate.
Materials and Methods: We reviews patients newly diagnosed and
received TURBT surgery in our hospital from 2011 to 2014. Patients who
were loss of following up/ under unresectable status were all excluded. The
age, body weight, height and sex were all recorded. The number, grade and
stage of tumor were all recorded. Also, the complication during the
operation were also reviewed based on medical record.
Results: From2011 to 2014, therewere 10 patients received laser TURBTand
52 patients received traditional TURBTsurgery. The detrusormuscle harvest
rate was 91.6% in Laser TURBT group and 77.4% in traditional TURBT group
(p¼0.44). Themean following timewas 25.5months (Median 23.1months).
The total recurrence ratewas 11.9% (2/9) in Laser TURBTgroupand22.4% (13/
58) in cTa/ cT1/ cT2 group. In comparison the recurrence rate inT1/ Ta group,
the detrusormuscle (+) group has lower recurrence rate in both laser TURBT
group (25.0%) and traditional TURBTgroup (24.2%) than the detrusormuscle
() group (40%). All the procedures have no complication recorded.
Conclusion: The application of laser with En-bloc method in TURBT is a
good alternative which could increase the diagnosis accuracy and lower
the recurrence rate.
MP6-5.
COMPARISONS OF FUNCTIONAL OUTCOMES AND QUALITY OF LIFE
AFTER NEOBLADDER RECONSTRUCTION: PROSTATE-SPARING
CYSTECTOMY VERSUS RADICAL CYSTOPROSTATECTOMY
Chiang Po Hui, Chen Po Yen. Kaohsiung Chang Gung Medical Center,
Department of Urology, Taiwan
Purpose: To compare functional outcomes on erectile function, conti-
nence, voiding functions, and life quality among bladder patients under-
went neobladder reconstruction after prostate-sparing cystectomy (PSC)
and conventional radical cystoprostatectomy (CRC).
